See more : Moody’s Corporation (MCO) Income Statement Analysis – Financial Results
Complete financial analysis of Prenetics Global Limited (PRE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Prenetics Global Limited, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Basic Energy Services, Inc. (BASX) Income Statement Analysis – Financial Results
- Mongolia Energy Corporation Limited (MOAEY) Income Statement Analysis – Financial Results
- Vitasoy International Holdings Limited (0345.HK) Income Statement Analysis – Financial Results
- Airtouch Solar Ltd (ARTS.TA) Income Statement Analysis – Financial Results
- SOLIZE CORPORATION (5871.T) Income Statement Analysis – Financial Results
Prenetics Global Limited (PRE)
About Prenetics Global Limited
Prenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring system that allows users to take COVID-19 tests at point-of-care or at home utilizing the nucleic acid amplification test. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; Circle Medical, a diagnostic testing product; and Circle One and F1x/Fem. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 21.74M | 275.76M | 275.85M | 65.18M | 9.23M |
| Cost of Revenue | 12.91M | 144.21M | 169.72M | 38.83M | 6.52M |
| Gross Profit | 8.83M | 131.55M | 106.13M | 26.34M | 2.72M |
| Gross Profit Ratio | 40.61% | 47.71% | 38.47% | 40.42% | 29.41% |
| Research & Development | 11.66M | 15.52M | 10.56M | 2.78M | 2.99M |
| General & Administrative | 41.44M | 96.06M | 83.99M | 16.62M | 13.19M |
| Selling & Marketing | 8.24M | 13.30M | 21.93M | 6.49M | 4.77M |
| SG&A | 49.68M | 109.36M | 105.92M | 23.11M | 17.96M |
| Other Expenses | -606.84K | -149.23M | -7.93K | -513.86K | 40.15K |
| Operating Expenses | 60.74M | 124.88M | 116.48M | 25.38M | 20.94M |
| Cost & Expenses | 73.65M | 269.09M | 286.20M | 64.21M | 27.46M |
| Interest Income | 3.92M | 472.19K | 3.98K | 8.04K | 15.51K |
| Interest Expense | 119.66K | 3.99M | 228.18K | 59.57K | 69.39K |
| Depreciation & Amortization | 7.79M | 7.54M | 7.35M | 2.43M | 2.23M |
| EBITDA | -47.90M | -214.28M | -157.70M | -1.42M | -18.57M |
| EBITDA Ratio | -220.29% | 15.67% | -58.89% | -0.87% | -200.54% |
| Operating Income | -51.91M | 207.42M | -10.35M | 967.46K | -18.23M |
| Operating Income Ratio | -238.73% | 75.22% | -3.75% | 1.48% | -197.44% |
| Total Other Income/Expenses | -4.76M | -159.80M | -159.89M | -2.91M | -69.39K |
| Income Before Tax | -56.67M | -183.31M | -170.28M | -3.90M | -20.87M |
| Income Before Tax Ratio | -260.64% | -66.47% | -61.73% | -5.99% | -226.06% |
| Income Tax Expense | -269.36K | 7.15M | 3.73M | -1.94M | -677.47K |
| Net Income | -62.72M | -190.45M | -174.02M | -1.96M | -20.20M |
| Net Income Ratio | -288.48% | -69.06% | -63.08% | -3.01% | -218.73% |
| EPS | -5.58 | -37.57 | -14.77 | -0.27 | -2.73 |
| EPS Diluted | -5.58 | -37.57 | -14.77 | -0.27 | -2.73 |
| Weighted Avg Shares Out | 11.25M | 5.07M | 11.78M | 7.40M | 7.40M |
| Weighted Avg Shares Out (Dil) | 11.25M | 5.07M | 11.78M | 7.40M | 7.40M |
Prenetics Announces First Quarter 2024 Financial Results
First Quarter Revenue Increased 30.2% and Gross Profit Increased 159.8% from Prior Year Quarter
DYMO PARTNERS WITH TAYLOR TO OFFER CUSTOM PRE-PRINTED LABELS FOR DYMO LABELWRITER 5 SERIES PRINTERS
ATLANTA , June 5, 2024 /PRNewswire/ -- DYMO®, a leading provider of innovative labeling solutions and part of the Newell Brands global portfolio, and Taylor , a renowned name in custom label manufacturing, have announced a strategic partnership that makes...
Prenetics Announces Fourth Quarter and Full Year 2023 Financial Results
HONG KONG, April 01, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics-driven health sciences company, today announced unaudited financial results for the fourth quarter and full year ended December 31, 2023, along...
Prenetics Announces MOU for a Strategic Investment and 5-Year Research Collaboration with Metavisionaries to Pioneer R&D on the International Space Station
(From left: Dr. Ghada Alsaleh, Sonia Pawelczyk, Danny Yeung, Dr. James L. Green, Ahmed Alfandi, Dr. Tara Ruttley, Wasim Ahmed, Dr. Hilde Stenuit, Dr. Camille Alleyne at the MOU signing ceremony in Dubai, UAE Space Agency)
Prenetics Announces Third Quarter 2023 Financial Results
HONG KONG, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics-driven health sciences company, today announced financial results for the third quarter ended September 30, 2023, along with recent business updates.
Prenetics Global Limited Announces Reverse Stock Split
HONG KONG, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leading-genomics-driven health sciences company today announced that it will proceed with a reverse stock split of its outstanding ordinary shares at a ratio of 1-for-15.
Prenetics Announces Second Quarter 2023 Financial Results
HONG KONG, Sept. 15, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics-driven health sciences company, today announced financial results for the second quarter ended June 30, 2023, along with recent business updates.
Wall Street Analysts See Prenetics Global Limited (PRE) as a Buy: Should You Invest?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Should You Invest in Prenetics Global Limited (PRE) Based on Bullish Wall Street Views?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
7 Stocks to Buy for Their Massive Upside Potential
If Warren Buffett was your financial advisor, he might steer you toward reliable blue-chip investments, not wildly speculative stocks to buy now. Put another way, you're probably not going to find these enterprises listed among the holdings of Berkshire Hathaway...
Source: https://incomestatements.info
Category: Stock Reports